Georgia Life Sciences Designates Augusta as Newest BioReady® Community

Georgia is home to a dynamic and fast-growing life sciences industry—built on bold ideas, scientific risk-taking, and an unwavering commitment to improving patient outcomes. That progress depends on smart, forward-looking policies that support innovation, investment, and access to care. The Most Favored Nation (MFN) policy outlined in this week’s Executive Order threatens to undermine those goals. By tying U.S. drug reimbursement to artificially low prices set by foreign governments, MFN would effectively import price controls from systems that frequently delay—or outright deny—patient access to new therapies. This policy would have real and damaging consequences: stifling innovation, weakening our national leadership in biomedical R&D, and jeopardizing the survival of early-stage biotech companies that form the backbone of Georgia’s life sciences economy. The cost of these short-sighted policies is not theoretical. It means fewer life-saving therapies making it to market—especially for patients with rare, complex, or life-threatening diseases. Studies have repeatedly shown that countries with strict price controls suffer from slower access to breakthrough treatments, if they receive them at all. Georgia Life Sciences urges the Administration and Congress to reject policies that compromise patient care and biomedical progress. Instead, we must work together on balanced solutions that lower out-of-pocket costs for patients while preserving America’s innovation ecosystem. We remain committed to partnering with policymakers to ensure patients in Georgia—and across the country—continue to benefit from the scientific advances our sector delivers every day.

Strength in Science. Power in Numbers. In a year filled with political uncertainty, one thing is clear: Georgia’s life sciences industry must speak with a united voice. From federal policy shifts to state-level regulatory changes, the decisions being made are directly impacting funding, innovation pipelines, workforce policy, and healthcare access. If we don’t shape the narrative, someone else will. That’s why now is the time to join Georgia Life Sciences . Why Join Now? Policy Advocacy : Amplify your voice where it matters—at the Capitol and in Congress. Visibility & Influence: Be recognized as part of Georgia’s innovation backbone. Networking & Growth : Tap into a thriving ecosystem of researchers, entrepreneurs, investors, and executives. Collective Impact: The greater our numbers, the stronger our position. The Stakes Are High As political tides shift, science needs champions—not just in the lab, but at the table where decisions are made. Your membership isn’t just a badge—it’s a signal that science will not sit on the sidelines. Join Today. Lead Tomorrow. Membership applications received by June 30 qualify for a 50% discount on first year dues . Applies to new memberships only.